Illustrative image – not actual.The Central Government has approved the Strides Arcolab-Mylan $1.6 billion (Rs 9,920 crore) deal, overruling the concerns raised by the Department of Industrial Policy and Promotion (DIPP) and Ministry of Health.
In February 2013, US-based Mylan and Bangalore-based Strides Arcolab signed the agreement under which the US drug major was to acquire Agila Specialties, the injectible medicine business of Strides. However, according to DIPP, the brownfield investment in pharmaceuticals hurts domestic companies. Regulators have also been concerned in case Mylan steers cancer drugs made in India to the US market, reducing domestic availability.
Now, the deal will be brought to the Cabinet Committee on Economic Affairs (CCEA), under the existing policy, to get the final approval.
The Foreign Investment Promotion Board (FIPB), had kept its approval on the deal in abeyance till there was clarity on "brownfield" foreign direct investment (FDI) norms - one in which acquisition is built into a new project.
